Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome

Objective: As the use of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) increases in the management of advanced ovarian cancer, therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may be observed more frequently. Strategies for management of this unique...

Full description

Bibliographic Details
Published in:	Gynecologic Oncology Reports
Main Authors:	Shilpa Mokshagundam, Mrinal M. Patnaik, Luigi A. DeVitis, Simrit K. Warring, Megan E. Grudem, Matthew S. Block
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Subjects:	PARP inhibitor Myelodysplastic syndrome Clonal hematopoiesis Stem cell transplantation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578925001316

Similar Items

Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome
by: Kevin G. Shim, et al.
Published: (2025-08-01)

Predictors of vascular disease in myelodysplastic syndromes
by: Mark G. Faber, et al.
Published: (2020-11-01)

Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential
by: Anna Maria Cacic, et al.
Published: (2023-12-01)

Is Unidentified Cytopenia Truly Unidentified? Or Are We Overlooking Clonality?
by: Elcin Erdogan Yucel, et al.
Published: (2026-05-01)

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
by: Yannick Simoni, et al.
Published: (2022-07-01)

Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review
by: Chen Wang, et al.
Published: (2022-09-01)

Lymphoblastic transformation of myelodysplastic syndrome
by: Carmen Silvia Passos Lima, et al.

Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes
by: Matheus F. Bezerra, et al.
Published: (2022-07-01)

Clinical, laboratory and genetic characteristics of VEXAS syndrome: a study on behalf of GESMD
by: Marta Fonseca-Santos, et al.
Published: (2026-04-01)

Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
by: Lei Huang, et al.
Published: (2025-07-01)

Predicting response to immunomodulatory therapy as an element of a strategy for preventing emergencies in myelodysplastic syndrome
by: H.S. Starodub, et al.
Published: (2026-02-01)

Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms
by: Kelly S. Chien, et al.
Published: (2024-03-01)

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
by: Seiichi Okabe, et al.
Published: (2023-06-01)

The role of T2*-weighted gradient echo in the diagnosis of tumefactive intrahepatic extramedullary hematopoiesis in myelodysplastic syndrome and diffuse hepatic iron overload: a case report and review of the literature
by: Abel A. Belay, et al.
Published: (2018-01-01)

Ultralow-dose irradiation enables engraftment and intravital tracking of disease initiating niches in clonal hematopoiesis
by: Kevin Lee, et al.
Published: (2024-09-01)

Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities
by: Chiara Caprioli, et al.
Published: (2022-02-01)

Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer
by: Yulin Wang, et al.
Published: (2025-01-01)

Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort
by: Rachel Jaber Chehayeb, et al.
Published: (2024-11-01)

Evaluation of clonal hematopoiesis and mosaic loss of Y chromosome in cardiovascular risk: An analysis in prospective studies
by: Sami Fawaz, et al.
Published: (2024-12-01)

Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD
by: Stefan Kuhnert, et al.
Published: (2022-07-01)

Clonal hematopoiesis as a novel risk factor for type 2 diabetes mellitus in patients with hypercholesterolemia
by: Min Joo Kim, et al.
Published: (2023-06-01)

A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
by: Aneeqa Ahsan Zafar, et al.
Published: (2020-04-01)

Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
by: Cristian C. Taborda, et al.
Published: (2024-07-01)

Dynamic tracking of native precursors in adult mice
by: Suying Liu, et al.
Published: (2024-12-01)

Clonal Hematopoiesis, a Risk Condition for Developing Myeloid Neoplasia
by: Ugo Testa, et al.
Published: (2025-04-01)

Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome
by: Sophonie Shilonite Njonou Noujiep, et al.
Published: (2026-04-01)

Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets
by: Forouzan Bahmani, et al.
Published: (2025-05-01)

Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients
by: Yuenv Wu, et al.
Published: (2017-08-01)

Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis
by: LaShanale Wallace, et al.
Published: (2023-10-01)

Genetic association between endometrial cancer and clonal hematopoiesis: A Mendelian randomization study
by: Yun Feng, et al.
Published: (2025-05-01)

Natural history of chronic idiopathic neutropenia of the adult
by: Bruno Fattizzo, et al.
Published: (2024-09-01)

Inferring clonal somatic mutations directed by X chromosome inactivation status in single cells
by: Ilke Demirci, et al.
Published: (2024-08-01)

Cutaneous Langerhans cell histiocytosis and other systemic inflammatory or autoimmune disease manifestations in the setting of clonal hematopoiesis
by: Giby V. George, et al.
Published: (2024-10-01)

Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity
by: Helin Tercan, et al.
Published: (2024-01-01)

Fully Automated, High-Dose Radiosynthesis of [<sup>18</sup>F]PARPi
by: Anna Pacelli, et al.
Published: (2022-07-01)

Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study
by: Xinyu Guo, et al.
Published: (2024-07-01)

Common in atherogenesis and carcinogenesis: clonal hematopoiesis
by: A. A. Sleptsov, et al.
Published: (2023-11-01)

Clonal hematopoiesis of indeterminate potential: clinical relevance of an incidental finding in liquid profiling
by: Hoermann Gregor
Published: (2022-08-01)

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy
by: Lea Naomi Eder, et al.
Published: (2023-01-01)

Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment
by: Haixia Liu, et al.
Published: (2023-04-01)